Truist analyst David MacDonald lowered the firm’s price target on Humana (HUM) to $305 from $325 and keeps a Hold rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Proposal to cut Medicaid spending aims for GOP middle ground, WSJ says
- Humana call volume above normal and directionally bullish
- Humana’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating Amid Star Ratings Challenges
- Humana’s Hold Rating: Balancing Positive EPS Guidance with Legal and Margin Uncertainties
- U.S. files False Claims Act complaint against three insurers, three brokers